ArticleCancer immunology, immunotherapy : CII2026
PD-1 inhibitors combined with induction chemotherapy followed by chemoradiotherapy in HPV-negative locally advanced head and neck squamous cell carcinoma: a real-world study.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo compare the efficacy of induction chemotherapy with or without PD-1 inhibitors followed by chemoradiotherapy (CCRT) among patients with human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma (LA-HNSCC). MATERIALS AND
methodsWe retrospectively reviewed patients with HPV-negative LA-HNSCC who received induction chemotherapy with or without PD-1 inhibitors followed by CCRT between January 2018 and June 2023. Overall survival (OS), disease-free survival (DFS), and treatment-related adverse effects (TRAEs) were compared between the two groups overall and then in one-to-one propensity-score matched (PSM) cohorts.
resultsA total of 289 eligible patients were enrolled, with 120 patients received induction chemotherapy (the IC group), and 169 patients received induction chemotherapy combined with PD-1 inhibitors (the IC-IO group). Median follow-up was 39.3 months (range: 37.5-41.5 months). After PSM, objective response rate (ORR) was not significantly different in the IC-IO group versus the IC group (81.5% vs 74.1%, P = 0.19). The IC-IO group (vs. the IC group) had a superior 2-year OS (84.3% vs. 68.2%, P = 0.002) and DFS (74.1% vs. 56.9%, P = 0.005). G3/4 TRAEs between the two matched groups were comparable both during induction (11.1% vs 11.1%, P = 1.000) or CCRT (29.6% vs 38.9%, P = 0.152) phases. For the IC-IO group, no significant differences in OS (P = 0.68) or DFS (P = 0.29) were observed in the subset with versus without PD-1 inhibitors concurrently with CCRT.
conclusionsThe addition of PD-1 inhibitors to IC significantly improves outcomes with tolerable TRAEs in patients with HPV-negative LA-HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.